Medacta Group SA acquires Parcus Medical to accelerate expansion in Sportsmed
|
Medacta Group SA
/ Key word(s): Acquisition/Acquisition
Press Release Medacta Group SA acquires Parcus Medical to accelerate expansion in Sportsmed
The acquisition will enable Medacta to accelerate its expansion of its sports medicine offering, while also gaining access to additional US sales agents and distributors in over 45 countries thereby enlarging its global reach to customers. With the acquisition, Parcus Medical will be integrated in the Medacta Sportsmed business line accelerating the go-to-market strategy for a swift future growth in Sportsmed. As part of the acquisition, Medacta will take over Parcus’ US manufacturing site in Florida, allowing Medacta to be vertically integrated also in Sportsmed. Parcus’ portfolio offers a diverse product family in sports medicine that helps facilitate surgical procedures in the shoulder, knee, hip and foot & ankle. The acquisition significantly expands and excellently complements Medacta’s sports medicine solution offerings in Sportsmed. Medacta will be able to leverage Parcus Medical’s brands and innovations to better serve the market. Furthermore, Medacta will be able to capitalize opportunities due to its strong presence in the fast-growing US Ambulatory Surgical Centre (ASC) market. The acquisition also underscores Medacta’s dedication to improving patient outcome and healthcare sustainability. Francesco Siccardi, CEO of Medacta, commented: “Parcus Medical is a great addition to Medacta’s Sportsmed business with its complementary product portfolio and trusted brands. The acquisition is in line with our strategy to seize opportunities to further perfect our offerings to sustainably improve patient outcome and patient satisfaction. I warmly welcome all 50 employees to Medacta, all partners, sales agents, distributors and customers.” Terms of the transaction The transaction was financed from existing resources. Both parties have agreed not to disclose any further details. The acquisition has already been completed. Advisors BCLP served as legal counsel and Rothschild & Co acted as exclusive financial advisor to Medacta.
Contact Medacta Anja Pomrehn Group VP Investor & Financial Media Relations & ESG Phone: +41 91 696 14 95
About Medacta Medacta is an international company specializing in the design, production, and distribution of innovative orthopedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 60 countries. Disclaimer This press release has been prepared by Medacta Group SA ('Medacta' and together with its subsidiaries, 'we', 'us' or the 'Group'). The information contained in the press release does not purport to be comprehensive and is not to be taken as containing any securities advice, recommendation, offer or invitation to subscribe for, purchase or redeem any securities regarding Medacta. Forward-looking information This press release has been prepared by Medacta and includes forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions. There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release. Important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved. Related Trademarks Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. AMIS®, GMK® SpheriKA, MyShoulder®, NextAR™, NextAR™ Spine, MyKA™, MySpine®.
End of Media Release |
| Language: | English |
| Company: | Medacta Group SA |
| Strada Regina | |
| 6874 Castel San Pietro | |
| Switzerland | |
| Phone: | +41 91 696 6060 |
| E-mail: | info@medacta.ch |
| Internet: | www.medacta.com |
| ISIN: | CH0468525222 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2096844 |
| End of News | EQS News Service |
|
|
2096844 07.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.